November 18, 2026
Health news, explained with evidence
LIVE

Clinical Trial Finds Pelacarsen Lowers Lipoprotein(a) Without Reducing Cardiovascular Events

🧠 AI Analysis 2 min read 👁 3

A major international trial revealed that while the monthly injection pelacarsen successfully reduces lipoprotein(a) levels, it does not decrease major adverse cardiovascular events in adults with existing heart disease.

Clinical Trial Finds Pelacarsen Lowers Lipoprotein(a) Without Reducing Cardiovascular Events🧠AI Analysis

Photo: Medical Xpress

Key points

  • Pelacarsen reduced lipoprotein(a) levels by roughly 78 percent at 12 months.
  • The international trial followed over 8,300 patients with preexisting heart disease for a median of 4.7 years.
  • Major adverse cardiovascular events occurred at similar rates between the treatment and placebo groups.

An investigational therapy known as pelacarsen successfully reduced lipoprotein(a) levels in adults with preexisting cardiovascular disease, but failed to lower the overall incidence of major adverse cardiovascular events, according to a study published in the New England Journal of Medicine. The findings were simultaneously presented at the American Heart Association Scientific Sessions in Chicago.

Led by Dr. Leslie Cho and senior author Dr. Steven E. Nissen from the Cleveland Clinic, the international, randomized, placebo-controlled trial followed 8,322 participants over a median of 4.7 years. Patients received either monthly subcutaneous injections of pelacarsen or a placebo. Baseline median lipoprotein(a) levels stood at 236 nmol/L. After one year, the treatment group achieved a dramatic 78 percent reduction, bringing median levels down to 64.4 nmol/L compared to 233.4 nmol/L in the placebo group.

Despite successfully lowering the biomarker, primary endpoint events occurred in 12.3 percent of patients receiving pelacarsen and 12.1 percent of those taking the placebo. Dr. Nissen noted in a statement that the neutral outcome was unexpected and surprising to the medical community. The study also observed serious adverse events in 37.3 percent of the pelacarsen cohort and 41.1 percent of the placebo group.

What to know: While biomarker reduction is often used as a surrogate marker for lower cardiovascular risk, this trial demonstrates that lowering lipoprotein(a) via pelacarsen does not automatically translate to fewer cardiac events in this patient population. Readers should consult a qualified healthcare provider for personalized medical decisions regarding heart health management.

Source Medical Xpress — medicalxpress.com/news/2026-11-aha-pelacarsen-lipoproteina-major-advers… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.